Responses
Regular and young investigator award abstracts
Clinical trials in progress
407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.